PMID- 28357569
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20181113
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 105
IP  - 5
DP  - 2017 May
TI  - Leukemic stem cells: identification and clinical application.
PG  - 549-557
LID - 10.1007/s12185-017-2221-5 [doi]
AB  - Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) represent a 
      low-frequency subpopulation of leukemia cells that possess stem cell properties 
      distinct from the bulk leukemia cells, including self-renewal capacity and drug 
      resistance. Due to these properties, LSCs are supposed to facilitate the 
      development of relapse. The existence of LSCs is demonstrated by the ability to 
      engraft and initiate human AML in immune-compromised mouse models. Although 
      several lines of evidence suggest the complex heterogeneity of phenotypes 
      displayed by LSC, many studies consider the CD34+/CD38- compartment as the most 
      relevant. To increase the understanding of the true LSC, techniques such as 
      multicolor flow cytometry, side-population assay and ALDH assay are utilized in 
      many laboratories and could aid in this. A better understanding of different LSC 
      phenotypes is necessary to enhance risk group classification, guide clinical 
      decision-making and to identify new therapeutic targets. These efforts to 
      eliminate LSC should ultimately improve the dismal AML outcome by preventing 
      relapse development.
FAU - Hanekamp, Diana
AU  - Hanekamp D
AD  - Department of Hematology, VU University Medical Center, PO Box 7057, 1007 MB, 
      Amsterdam, The Netherlands.
FAU - Cloos, Jacqueline
AU  - Cloos J
AD  - Department of Hematology, VU University Medical Center, PO Box 7057, 1007 MB, 
      Amsterdam, The Netherlands. j.cloos@vumc.nl.
AD  - Department of Paediatric Oncology/Hematology, VU University Medical Center, 
      Amsterdam, The Netherlands. j.cloos@vumc.nl.
FAU - Schuurhuis, Gerrit Jan
AU  - Schuurhuis GJ
AD  - Department of Hematology, VU University Medical Center, PO Box 7057, 1007 MB, 
      Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170329
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Antigens, CD34)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1
MH  - Animals
MH  - Antigens, CD34
MH  - Biomarkers, Tumor
MH  - Flow Cytometry
MH  - Humans
MH  - Immunocompromised Host
MH  - *Leukemia, Myeloid, Acute/diagnosis/pathology
MH  - Mice
MH  - Neoplasm Recurrence, Local/prevention & control
MH  - *Neoplastic Stem Cells
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Flow cytometry
OT  - Immunophenotypic
OT  - Leukemic stem cells
EDAT- 2017/03/31 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/03/31 06:00
PHST- 2017/03/15 00:00 [received]
PHST- 2017/03/23 00:00 [accepted]
PHST- 2017/03/22 00:00 [revised]
PHST- 2017/03/31 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/03/31 06:00 [entrez]
AID - 10.1007/s12185-017-2221-5 [pii]
AID - 10.1007/s12185-017-2221-5 [doi]
PST - ppublish
SO  - Int J Hematol. 2017 May;105(5):549-557. doi: 10.1007/s12185-017-2221-5. Epub 2017 
      Mar 29.